Squamous Cell Lung Carcinoma Overview

Save information for later
Sign Up

Learn About Squamous Cell Lung Carcinoma

Condition 101 content is not available at this time, but we are continually updating the site. Please check back.

However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.

Who are the top Squamous Cell Lung Carcinoma Local Doctors?
Christine Hann
Elite in Squamous Cell Lung Carcinoma
Elite in Squamous Cell Lung Carcinoma

Johns Hopkins Bayview Medical Center

300 Mason Lord Drive, Kimmel Cancer Center, Kimmel Cancer Center, 
Baltimore, MD 
Languages Spoken:
English
Offers Telehealth

Christine L Hann, completed her MD and Ph.D. at Jefferson Medical College/Thomas Jefferson University follwed by an internal medicine residency at the University of Chicago Hospitals. Following a fellowship at Johns Hopkins University in Hematology and Oncology, Dr. Hann joined the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center as a member of the Upper Aerodigestive Cancer Program and sees patients with non-small cell and small cell lung cancer. Dr. Hann's research focus is on developing novel therapeutics for lung cancer, particularly small cell lung cancer (SCLC) and neuroendocrine tumors (NETs) such as carcinoid tumors of the lung. As a faculty member she is involved in both clinical and laboratory research. Specific research projects include: 1) Studying mechanisms of resistant to small molecule inhibitors of the antiapoptotic protein, BCL-2 using patient-derived xenograft models. Her preclinical work has led to an NCI-sponsored Phase 1/2 clinical trial combining a BCL-2 inhibitor with a TORC1/2 inhibitors which is currently underway (NCT03366103). 2) Preclinical evaluation of various therapeutics including epigenetic modulators (LSD1 inhibitors) and nanoliposome chemotherapy in SCLC PDXs; 3) Modeling and characterizing chemoradiotherapy resistance in preclinical models of SCLC. She, along with Dr. Luigi Marchionni in Biostatistics and Dr. Phuoc Tran in the Department of Radiation Oncology, were recently awarded a 5-year NCI-sponsored U01 grant to study mechanisms of chemoradiation resistance in SCLC. Dr. Hann is PI of several trials in SCLC and NSCLC and is leading investigator-initiated clinical trials in SCLC and NETs. Dr. Hann is rated as an Elite provider by MediFind in the treatment of Squamous Cell Lung Carcinoma. Her top areas of expertise are Small Cell Lung Cancer (SCLC), Lung Cancer, Squamous Cell Lung Carcinoma, and Non-Small Cell Lung Cancer (NSCLC).

Jason N. Macklis
Distinguished in Squamous Cell Lung Carcinoma
Hematology | Oncology
Distinguished in Squamous Cell Lung Carcinoma
Hematology | Oncology

Advocate Lutheran General Cancer Institute

1700 Luther Ln 1st & 2nd Fl, 
Park Ridge, IL 
Languages Spoken:
English

Jason Macklis is a Hematologist and an Oncologist in Park Ridge, Illinois. Dr. Macklis is rated as a Distinguished provider by MediFind in the treatment of Squamous Cell Lung Carcinoma. His top areas of expertise are Pleuropulmonary Blastoma, Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), EGFR Positive Lung Cancer, and Bone Marrow Aspiration.

 
 
 
 
Learn about our expert tiers
Learn More
Thomas D. Weyburn
Distinguished in Squamous Cell Lung Carcinoma
Hematology | Oncology
Distinguished in Squamous Cell Lung Carcinoma
Hematology | Oncology

Advocate Infusion Center

525 E Congress Pkwy, Ste 300, 
Crystal Lake, IL 
Languages Spoken:
English
Offers Telehealth

Thomas Weyburn is a Hematologist and an Oncologist in Crystal Lake, Illinois. Dr. Weyburn is rated as a Distinguished provider by MediFind in the treatment of Squamous Cell Lung Carcinoma. His top areas of expertise are Pleuropulmonary Blastoma, Lung Cancer, Small Cell Lung Cancer (SCLC), and Familial Colorectal Cancer.

What are the latest Squamous Cell Lung Carcinoma Clinical Trials?
A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of Lutetium [177Lu]-BL-ARC001 Injection in Patients With Locally Advanced or Metastatic Lung Cancer, Breast Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors

Summary: This study is an open, multicenter, dose-escalation and cohort-expansion non-randomized phase I clinical trial to evaluate the safety, tolerability, pharmacokinetic characteristics and preliminary efficacy of Lutetium \[177Lu\] BL-ARC001 in patients with locally advanced or metastatic solid tumors.

Match to trials
Find the right clinical trials for you in under a minute
Get started